Atezolizumab First PD-L1 Inhibitor Approved for the Treatment of Patients with Metastatic NSCLC

Online First - FDA Approvals, News & Updates
On October 18, 2016, atezolizumab (Tecentriq; Genentech), a PD-L1 inhibitor, was approved by the FDA for patients with metastatic non–small-cell lung cancer (NSCLC) associated with the EGFR or ALK genetic mutations whose disease progressed during or after treatment with platinum-containing chemotherapy.
Related Items
February 8, 2019 - FDA Approvals, News & Updates
In the News: Oncology - January 2019 published on February 1, 2019 in Breaking News, FDA Approvals, News & Updates
February 1, 2019 - FDA Approvals, News & Updates
In the News: Oncology - January 2019 published on February 1, 2019 in Breaking News, FDA Approvals, News & Updates
I. New Drugs
TOP - February 2019, Vol 12, No 1 published on January 29, 2019 in FDA Approvals, News & Updates
II. New Indications
TOP - February 2019, Vol 12, No 1 published on January 29, 2019 in FDA Approvals, News & Updates
Government Shutdown Impacts FDA Drug Approvals
In the News: Oncology - February 2019 published on January 14, 2019 in Breaking News, FDA Approvals, News & Updates
Braftovi Plus Mektovi a New Combination for Unresectable or Metastatic Melanoma with BRAF Mutation
JHOP Web Exclusives published on November 30, 2018 in FDA Approvals, News & Updates
Lenvima Now Approved for Unresectable Hepatocellular Carcinoma
JHOP Web Exclusives published on November 13, 2018 in FDA Approvals, News & Updates
FDA News - September 2018
TON - September 2018, Vol 11, No 4 published on September 19, 2018 in FDA Approvals, News & Updates
A Dynamic FDA Has Led to More Rapid Cancer Drug Development
Wayne Kuznar
JHOP Web Exclusives published on July 17, 2018 in FDA Approvals, News & Updates, In the News, Online Only
Welcome to the Third Annual Oncology Guide to New FDA Approvals
2018 Third Annual Oncology Guide to New FDA Approvals published on May 9, 2018 in FDA Approvals, News & Updates
Last modified: October 31, 2016